Relmada Therapeutics Enterprise Value Over E B I T D A Over Time
| RLMD Stock | USD 0.37 0.05 11.90% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Relmada Therapeutics Performance and Relmada Therapeutics Correlation. Relmada |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relmada Therapeutics. If investors know Relmada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relmada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.86) | Return On Assets (0.59) | Return On Equity (1.00) |
The market value of Relmada Therapeutics is measured differently than its book value, which is the value of Relmada that is recorded on the company's balance sheet. Investors also form their own opinion of Relmada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relmada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relmada Therapeutics' market value can be influenced by many factors that don't directly affect Relmada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Relmada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Relmada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Enterprise Value Over E B I T D A Analysis
Compare Relmada Therapeutics and related stocks such as Cytokinetics, Dice Molecules Holdings, and Edgewise Therapeutics Enterprise Value Over E B I T D A Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CYTK | (1.2049) | (1.0562) | (1.4279) | (4.7209) | (18.7775) | (9.6546) | 29.8643 | (2.8396) | (4.1215) | (7.6366) | (16.0949) | (20.7646) | (14.5706) | (19.0537) | (18.1) |
| EWTX | (152) | (152) | (152) | (152) | (152) | (152) | (152) | (152) | (152) | (152) | (90.0694) | (11.0746) | (1.961) | (5.4647) | (5.74) |
| DYN | 50.4072 | (1.9745) | 30.5929 | 23.5933 | 28.2445 | 13.2765 | 97.0387 | 12.5815 | (50.5568) | (73.4149) | (0.0251) | (2.9483) | (2.7965) | (2.9964) | (2.85) |
| THRD | (385) | (385) | (385) | (385) | (385) | (385) | (385) | (385) | (385) | (385) | (385) | (49.9309) | 3.2809 | (5.5146) | (5.79) |
| PMVP | (67.2911) | (67.2911) | (67.2911) | (67.2911) | (67.2911) | (67.2911) | (67.2911) | (67.2911) | (67.2911) | (65.0904) | (69.1099) | (15.2003) | (3.9407) | (1.5775) | (1.66) |
| RVMD | (35.0246) | (35.0246) | (35.0246) | (35.0246) | (35.0246) | (35.0246) | (35.0246) | (35.0246) | (24.672) | (34.7535) | (25.1691) | (9.9621) | (7.614) | (6.1241) | (6.43) |
| STTK | (57.6314) | (57.6314) | (57.6314) | (57.6314) | (57.6314) | (57.6314) | (57.6314) | (57.6314) | (57.6314) | (32.6432) | (55.934) | (6.0477) | (0.5416) | (2.0809) | (2.18) |
| CSBR | 39.45 | (2.9357) | (1.3723) | (9.088) | (4.1725) | (3.0487) | (3.7446) | (47.1173) | 114 | (118) | 399 | 45.5744 | (31.0744) | (13.9529) | (13.26) |
| IPSC | (61.0383) | (61.0383) | (61.0383) | (61.0383) | (61.0383) | (61.0383) | (61.0383) | (61.0383) | (61.0383) | (61.0383) | (24.2222) | (9.3346) | (2.1907) | (1.6317) | (1.71) |
| BCYC | (15.3035) | (15.3035) | (15.3035) | (15.3035) | (15.3035) | (15.3035) | (15.3035) | (5.7841) | (4.473) | (0.464) | (4.4346) | (17.652) | (5.1621) | (0.8835) | (0.93) |
| RAPT | (8.914) | (8.914) | (8.914) | (8.914) | (8.914) | (8.914) | (8.914) | (8.914) | (9.0335) | (12.4217) | (8.672) | (14.3964) | (7.2491) | (7.248) | (7.61) |
| NAMS | (35.4021) | (35.4021) | (35.4021) | (35.4021) | (35.4021) | (35.4021) | (35.4021) | (35.4021) | (35.4021) | (35.4021) | (35.4021) | (3.9101) | 69.9181 | (3.2644) | (3.1) |
| NUVB | (64.3039) | (64.3039) | (64.3039) | (64.3039) | (64.3039) | (64.3039) | (64.3039) | (64.3039) | (64.3039) | (64.3039) | (25.5788) | (17.378) | (2.6709) | (2.9304) | (3.08) |
Relmada Therapeutics and related stocks such as Cytokinetics, Dice Molecules Holdings, and Edgewise Therapeutics Enterprise Value Over E B I T D A description
My Equities
My Current Equities and Potential Positions
| Relmada Therapeutics | RLMD |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.37
Check out Relmada Therapeutics Performance and Relmada Therapeutics Correlation. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Relmada Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.